Navigation Links
Simpulse® PLUS System

ProductsSimpulse® PLUS System
Company Davol, Inc.
Item Simpulse® PLUS System
Features 
  • Provides an innovative system for enhanced wound management which emphasizes performance, simplicity, safety, value, and support
  • Provides fine variable irrigation pressure control
  • Convenient trigger lock allows constant lavage
  • Connects quickly to any nitrogen/air source
  • Description Davol® pulsed lavage systems deliver the performance needed for quick, efficient removal of necrotic tissue, bacteria, and foreign material. Each provides controlled pressure for optimal cleansing and irrigation while minimizing potential for cross contamination.
    Info Davol, Inc.
    Customer Service: (800) 556-6756
    Web site: http://www.davol.com/

    Related medicine products :

    1. Simpulse® VariCare™ System
    2. Silicone Oil Cannula System - 20 Gauge
    3. Silicone Oil Cannula System - 19 Gauge
    4. SuperVu Galilean System
    5. KOWA nonmyd 7 / VK-2 Digital Imaging System
    6. KOWA nonmyd a-D / VK-2 Digital Imaging System
    7. Refraction System RT-2100
    8. Odyssey Phacoemulsification System
    9. SIStem Phacoemulsification System
    10. Precisionist Phacoemulsification System
    11. Photon Laser Phacoemulsification System
    Breaking Medicine News(10 mins):Health News:NICE guidelines ration affordable osteoporosis drugs 2Health News:NICE guidelines ration affordable osteoporosis drugs 3Health News:Menopause Often Means Worsening Cholesterol 2Health News:Menopause Often Means Worsening Cholesterol 3Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 3Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 4Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 5Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 6Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 7Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 8Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 9Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 10Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 11Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 12Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 13Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 14Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 15Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 16Health News:New Board Gains Control of U.S. Shanghai Chemical Corporation 2Health News:Surgery on beating heart thanks to robotic helping hand 2
    Other Medicine News:Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 2Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 3Health News:Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue 2Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 2Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 3Health News:National study finds youth baseball-related injuries down 25 percent 2Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 2Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 3Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 4Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 2Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 3Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 4
    Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 1Imagenetix Inc to Present at the 2009 RedChip New York Equities Conference 14251 2Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 1Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 2Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 3Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 4Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 1Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 2Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 3Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associ 5055 4